A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
about
Herpes zoster in Germany: quantifying the burden of diseaseVaccines for preventing herpes zoster in older adultsVaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adultsVaccines for preventing herpes zoster in older adultsVaccination for preventing postherpetic neuralgiaVaccines for preventing herpes zoster in older adultsBayesian probability of success for clinical trials using historical data.Prevention strategies for herpes zoster and post-herpetic neuralgiaA health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.Safety and tolerability of zoster vaccine in adults ≥60 years old.Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or olderImmunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.A refresher on herpes zoster, current status on vaccination, and the role of the dermatologist.Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.Vaccination in the elderly: what can be recommended?Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.Immune response to a refrigerator-stable zoster vaccine.Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
P2860
Q21261833-65CC5EE7-D50D-4D9D-9512-834FDD0A83FCQ24186050-8AAFEF61-4ABF-4C2F-BC95-A8C16A5640B8Q24193819-760CF3A1-7CB7-41D5-BB70-92AEB60BF178Q24198256-C820A9A6-22E1-49A0-A381-8A77D6BB425BQ24235822-CB1BA6F1-A8A5-4F85-BC18-844B13E5D36FQ24235910-20E96EBD-612E-4D18-A192-70558F77F1D4Q30863734-B176CBE0-22FA-48B5-AEAF-5B07185583F5Q33562809-D3EF2DFC-BA83-4C47-B1A7-D247AE2D921BQ33894866-9666D309-B228-4BD0-BD4D-5A6EF6716E9DQ34635527-FAC8C23C-8035-4DA5-BC6B-2452F52BB799Q35667362-0B3397FD-2A62-4E69-BBA2-0C9EB96E6222Q35881283-F04DB7DC-82EE-42BF-8E99-2F9D5E078E76Q37190911-893DB6BB-1818-4745-B116-AB13AF06BDEBQ37521902-C940CAAC-210C-47EB-9D7C-8594B3C089A7Q37903995-2D71F52B-7463-45CA-BFCA-7B11BF252D79Q38120494-222AEDF6-2704-4453-8316-34067A61CF1FQ38220158-6AD5FB5C-0FFA-47C4-85E7-D308CE5C7CB5Q42273664-39480D10-1929-4F19-A793-D66CE7223B36Q42557105-96EC9A41-E7AA-4371-A5C4-172D0A6E5672Q47155538-E1A72AB8-4C51-4E62-ADD2-3FE846B8F6CEQ58553251-4D227010-A472-4D9D-BB63-41511F0981DA
P2860
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
A double-blind, randomized, co ...... table formulation of Zostavax.
@ast
A double-blind, randomized, co ...... table formulation of Zostavax.
@en
type
label
A double-blind, randomized, co ...... table formulation of Zostavax.
@ast
A double-blind, randomized, co ...... table formulation of Zostavax.
@en
prefLabel
A double-blind, randomized, co ...... table formulation of Zostavax.
@ast
A double-blind, randomized, co ...... table formulation of Zostavax.
@en
P2093
P2860
P356
P1476
A double-blind, randomized, co ...... table formulation of Zostavax.
@en
P2093
Doreen A Fernsler
Florian Schödel
Ivan S F Chan
James F Lawless
Jeffrey L Silber
Katia Schlienger
Larry I Gilderman
Neal Azrolan
Ruth Z Rutledge
Santosh C Sutradhar
P2860
P304
P356
10.1128/CVI.00310-07
P577
2007-12-12T00:00:00Z